Stocks/CAMP

CAMP

CAMP4 Therapeutics Corporation
Healthcare·Biotechnology
$4.39
$93M market cap
Claude Rating
3/10SELL
Revenue
$3.9M
Free Cash Flow
$-26.3M
Rev Growth
+50.8%
FCF Margin
-667.2%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
$3.50
Upside
-20.3%

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

2-Year Price History

$4.51-57.9%
$2.0$4.0$6.0$8.0$10volOct 24Jan 25Apr 25Aug 25Nov 25Feb 26May 26

Quarterly Financials & Projections

Quarterly Waterfall ($ M)
PeriodRevEBITDAOpInNIOCFFCFCapExCashDebtSharesROICIntCovEV/EBITDA
Est2027-Q43.0-16.8---17.4---16.2-0.1-33.9----------
Est2027-Q32.5-17.0---17.5---16.5-0.1-17.7----------
Est2027-Q21.8-17.1---17.5---16.7-0.1-1.2----------
Est2027-Q11.8-17.1---17.5---16.7-0.115.6----------
Est2026-Q42.0-17.0---17.4---16.6-0.132.3----------
Est2026-Q32.0-17.0---17.4---16.6-0.148.9----------
Est2026-Q22.2-17.2---17.6---16.7-0.065.5----------
Est2026-Q12.5-17.5---18.0---17.0-0.182.2----------
Act2026-Q11.3-12.6-13.1-18.3-11.0-11.0-0.099.22.157.9-29.7%----
Act2025-Q40.4-12.4-12.8-40.36.36.3-0.0109.52.051.9-26.1%----
Act2025-Q30.8-14.7-13.2-15.1-11.2-11.2-0.075.39.420.2-24.2%----
Act2025-Q21.5-12.6-13.0-12.6-10.3-10.3-0.039.17.120.2-26.1%----
Act2025-Q10.9-12.7-13.1-12.4-14.3-14.6-0.349.37.919.5-24.4%----
Act2024-Q40.7-13.6-14.0-13.3-11.3-11.6-0.364.08.719.5-24.3%----
Act2024-Q30.0-13.1-13.5-13.5-9.7-9.7-0.02.59.519.5-572.1%----
Act2024-Q20.0-12.2-12.7-12.6-13.4-13.6-0.212.610.215.8-495.3%----
Act2024-Q10.0-12.4-12.9-12.5-11.1-11.2-0.012.610.512.1-343.6%----
Act2023-Q30.4-11.9-12.3-11.7-6.6-6.8-0.238.6243.237.0-20.3%-7.6x--
Act2023-Q270.93.0-2.5-4.0-3.0-3.1-0.135.0244.136.6-4.1%1.8x--
Act2023-Q178.5-0.4-1.6-8.1-1.1-1.2-0.141.9245.336.1-2.6%-0.2x--
Act2022-Q478.91.6-3.6-4.73.8-0.6-4.444.9246.636.4-5.9%1.0x--
Act2022-Q372.8-4.5-5.3-7.5-10.1-11.4-1.347.7239.436.0-8.9%-3.1x--
Act2022-Q264.7-4.8-9.3-12.2-15.6-19.2-3.659.0246.435.7-15.2%-3.1x--
Act2022-Q168.4-3.4-4.4-9.2-7.5-10.5-3.079.2205.735.6-7.7%-0.9x--
Historical Valuation

Multiples vs the company's own history — cheap or rich relative to itself? Historical fiscal years, then TTM, then forward projections (E). Forward rows hold today's price against projected earnings, so the multiple compresses if the company grows into it.

YearPriceRev GrEBITDA %EBITDAEV/EBITDAEV/FCFP/EP/S
2022-3.9%-11
20245.22-99.8%-7882.1%-51n/mn/mn/m320.7×
20256.13+436.5%-1497.0%-52n/m17.0×
TTM4.39+160.5%-1327.8%-520.0×0.0×
2026E4.39+121.2%-7.9%-10.0×0.0×
2027E4.39+4.6%-7.5%-10.0×0.0×

EBITDA in reporting-currency $M. Historical multiples use year-end market cap (split-adjusted price history); TTM & forward years use today's.

AI Analysis

LLM Evaluations

Claude3/10SELLFV: $3.50

CAMP4 is a high-risk pre-clinical/early-clinical stage biotech with an innovative RNA-targeting platform but no near-term revenue drivers, massive ongoing dilution, and a toxic financing structure that could nearly double the share count at a 75% discount to current prices. The GSK collaboration validates the platform but the $440M in milestones are fully constrained (0% probability). Cash runway extends to 2028 but at the cost of 157%+ annual dilution. The lead program CMP-002 won't produce meaningful clinical data until 2027 at earliest. With the stock trading at ~$6.76 on a basic share count of 52M shares, the fully diluted count of ~96M shares implies a true per-share value well below the current price. The CEO's adoption of a 10b5-1 selling plan during this period is a further negative signal. While the science may be compelling, the financial engineering is deeply shareholder-unfriendly, and there are no near-term catalysts to drive re-rating before the dilutive second tranche hits.

Catalyst Positive Phase 1/2 clinical data from CMP-002 in SYNGAP1 (earliest 2H 2027) or additional large pharma collaboration deals validating the platform could unlock significant upside. GSK milestone achievements would also be catalytic.
Risk The toxic second tranche financing at $1.53/share for ~33M shares represents catastrophic dilution if triggered, effectively halving existing shareholders' ownership at a fraction of market value. Combined with the 12-18 month news vacuum before clinical data, downside risk is severe.
Trend
DETERIORATING
Mgmt
4/10
Quarter
4/10
Exp. Move
-5.0%

Latest Earnings Call

Transcript Summary

CalAmp’s Q3 FY24 results highlight a company in the midst of a rigorous turnaround. Revenue fell 32% year-over-year to $53.6 million, missing expectations due to weakness in the Telematics Service Provider (TSP) market. However, the company achieved a major technical milestone by finishing the migration of 8.5 million devices to its new DMCTC management platform, ending a 20-month resource drain. Strategic successes included a Toyota Genuine certification and an endorsement from Jaguar Land Rover for its SVR technology. To combat revenue declines, CalAmp implemented a $16 million cost-reduction plan, aiming for an EBITDA breakeven at $42 million in quarterly revenue. The company also secured a $45 million term loan from Lynrock Lake to improve liquidity ahead of a $230 million debt maturity in 2025. A leadership transition is underway, with Chris Adams named as the incoming CEO. Management noted that while TSP demand remains soft, early signs of stabilization are appearing. For the fourth quarter, CalAmp anticipates stable EBITDA as Industrial revenues normalize and TSP orders begin a gradual recovery. The focus remains on operational efficiency and leveraging new AI-driven products like Vision 2.1 to drive future growth.

Valuation & Metrics

Market Stats

Price$4.39
Market Cap$93M
Enterprise Value$-4M
P/S Ratio23.7x
P/FCF--
EV/FCF--
FCF Margin (TTM)-667.2%
FCF Yield-28.1%
Dividend Yield (TTM)--
Annual Dilution197.0%
CurrencyUSD

TTM Financial Snapshot

Revenue$3.9M
Net Income$-86.3M
Free Cash Flow$-26.3M

Revenue Growth (YoY)+50.8%
EBITDA Margin-1327.8%
Net Margin-2193.7%
FCF Margin-667.2%
CapEx % of Revenue0.0%
SBC % of Revenue79.7%
ROIC-26.5%
WC Change % Rev-10.9%
Interest Coverage--

DCF Fair Value Estimate

$-1.57
-135.8% upside
Fair Enterprise Value$-911M
− Net Debt$-97M
= Fair Equity$-91M
Revenue Growth4.6% → 8.0%
FCF Margin-667.2% → 20.0%
Discount Rate18.0%
Terminal EV/FCF25.0x

Forward Outlook & Risk

Short Interest

Short % of Float16.2%
Short Shares0.5M
Days to Cover6.5
Change (vs Prior)-3.8%
Short % Float History
16.20%+2.30pp
10.0%15.0%20.0%25.0%04-3007-1509-1511-1401-1504-30

Forward Projections & Estimates

NTM Revenue Growth+121.1%
Forward FCF Margin-769.2%
Forward EBITDA Margin-789.2%
Forward P/FCF--
Forward EV/FCF--
Forward Int. Coverage-1578.4x
Model Risk Score10/10
Bankruptcy Odds12%
Est. Borrow Rate18.0%
Terminal EV/FCF25.0x
LT Growth15.0%
LT FCF Margin20.0%

Employees

Headcount55
Revenue / Employee$71,527
Gross Profit / Employee$54,509
2024: 10,000 → 2025: 21,000 (110% CAGR)

Cash Runway

45.4months
WATCH

Institutional Ownership

Headline & net flow

NET BUYING

In Q1 2026 so far (quarter still filing), institutions are net buyers — bought 125.8% of float, sold 63.6%. 7 filers moved >1% of shares (4 buying, 3 selling).

Net flow · Q1 2026still filing
+62.3% of float (net)
Bought 125.8% · Sold 63.6%
47 filers reported (last quarter: 39)

Ownership composition

Active
173.4%(+122.3% YoY)
37 filers
hedge / family / endowment
Retail funds
Fidelity, Schwab, 401(k)
Passive
13.2%(+9.9% YoY)
7 filers
Vanguard, iShares, SPDR
Market makers
1.6%(+1.6% YoY)
2 filers
Citadel, Susquehanna
Insiders
25.1%
Form 4 — latest per insider
0%25%50%75%100%2024-122025-032025-062025-092025-122026-03
ActiveRetail fundsPassiveMarket makersRetail direct

Top holders

Fund$ valueCost basisΔ QoQΔ YoYα lifeFund AUM
JANUS HENDERSON GROUP PLC$27.9M$3.83+$0+$27.9M+1.2%$209.29B
5AM Venture Management, LLC$25.9M$4.11+$0+$13.0M+1.1%$360M
FMR LLC$21.8M$4.50+$67K+$18.4M-0.0%$1.89T
Vivo Capital, LLC$18.7M$3.24+$0+$18.7M-7.0%$1.20B
BALYASNY ASSET MANAGEMENT LLC$11.6M$6.00+$862K+$11.6M-0.4%$48.01B
Enavate Sciences GP, LLC$9.7M$5.22−$3.7M−$7.0M+11.5%$352M
a16z Capital Management, L.L.C.$9.4M$5.22+$0+$0+1.3%$1.29B
ADAGE CAPITAL PARTNERS GP, L.L.C.$8.6M$3.32−$974K+$8.6M-0.1%$64.61B
Trails Edge Capital Partners, LP$8.6M$6.13−$196K+$8.6M+13.5%$425M
VANGUARD CAPITAL MANAGEMENT LLCPassive$6.8M$4.41+$6.8M+$6.8M$4.04T
Stonepine Capital Management, LLC$6.1M$4.69+$5.1M+$6.1M-5.9%$113M
HARBOURVEST PARTNERS LLC$5.6M$5.22+$0+$0-5.6%$101M
SILVERARC CAPITAL MANAGEMENT, LLC$2.9M$3.00+$0+$2.9M-0.2%$843M
BlackRock, Inc.Passive$2.0M$5.56+$292K+$706K-0.2%$5.69T
GEODE CAPITAL MANAGEMENT, LLCPassive$1.7M$5.63+$205K+$985K+2.3%$1.61T
SummitTX Capital, L.P.$1.5M$4.41+$1.5M+$1.5M+2.3%$3.12B
SUSQUEHANNA INTERNATIONAL GROUP, LLPMM$1.5M$4.41+$1.5M+$1.5M-0.6%$77.14B
VANGUARD FIDUCIARY TRUST COPassive$860K$4.41+$860K+$860K$395.83B
STATE STREET CORPPassive$648K$4.67+$473K+$532K-0.2%$2.89T
TWO SIGMA INVESTMENTS, LP$480K$3.18+$63K+$480K-0.9%$117.03B
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.

Trading behavior

Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
+0.46%
avg per quarter
Holders (ex-self)
+0.61%
excl. this stock
Buyers (this Q)
-3.19%
21 buyers · $0.02B in
Sellers (this Q)
+7.40%
10 sellers · $0.02B out
alpha coverage: 96% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-7.0%
how holders react when this stock falls
On quiet Qs
-2.5%
−10% to +10% baseline
On rallies (+10%+)
+8.3%
how they react when this stock rises
Holders' portfolio flow this Q
-9.8%
outflows — trims may be forced
Sellers' portfolio flow this Q
-3.1%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-6.8%
Holder mid (any stock)
-2.5%
Holder rally (any stock)
-6.7%

Top Holders Over Time

5-year share-count history (top 10 holders by peak, incl. exited) + price

08.6M17.2M25.8M34.4M$1.45$2.62$3.79$4.96$6.132024-122025-032025-062025-092025-122026-03
hover the chart for per-quarter detailprice (right axis)
JANUS HENDERSON GROUP PLC6.3M5AM Venture Management, LLC5.9MFMR LLC4.9MVivo Capital, LLC4.2MEnavate Sciences GP, LLC2.2MBALYASNY ASSET MANAGEMENT LLC2.6MADAGE CAPITAL PARTNERS GP, L.L.C.2.0Ma16z Capital Management, L.L.C.2.1MTrails Edge Capital Partners, LP1.9MHARBOURVEST PARTNERS LLC1.3M

Analyst Coverage

Analyst Coverage
Price Targets
Last Year (1 analysts)$7.005950.0%
Current Price$4.39
Analyst Ratings
16
7
Buy: 16Hold: 7Sell: 1Consensus: Buy
Consensus Estimates
QuarterRevenueEBITDANet IncEPSEPS Range# Analysts
2026 Q32M-1M-9M$-0.16$-0.21 – $-0.124
2026 Q42M-1M-9M$-0.16$-0.25 – $-0.042
2027 Q12M-1M-10M$-0.17$-0.27 – $-0.052
2027 Q22M-1M-11M$-0.18$-0.30 – $-0.051
2027 Q32M-1M-11M$-0.19$-0.31 – $-0.051
2027 Q42M-1M-12M$-0.21$-0.34 – $-0.062
2028 Q11M-1M-13M$-0.23$-0.37 – $-0.063
2028 Q21M-1M-13M$-0.23$-0.37 – $-0.062
2028 Q31M-1M-13M$-0.23$-0.37 – $-0.062
2028 Q41M-1M-13M$-0.23$-0.38 – $-0.063

Corporate

Executive Compensation (2023-2025)

Direct Pay$12.6M
Incentive & Other$15.9M
Total Compensation$28.5M
% of Revenue18.4%

Insider Trading (last 12mo)

Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$55K
4 txns · 4 insiders · 33,331 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$8.50M
3 txns · 3 insiders · 5,555,554 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
DateSideInsiderTitleSharesPriceDollarsOwned $
2025-09-11BUY5AM Partners VI, LLC10 percent owner2,941,176$1.53$4.50M$4.50M
2025-09-11BUYGold Kellyofficer: Chief Financial Officer6,060$1.65$10K$112K
2025-09-11BUYMandel-Brehm Joshdirector, officer: Chief Executive Officer6,060$1.65$10K$459K
2025-09-11BUYMaricich Yuriofficer: Chief Medical Officer6,060$1.65$10K$10K
2025-09-11BUYNashat Amirdirector, 10 percent owner: 1,307,189$1.53$2.00M$4.32M
2025-09-11BUYPolaris Management Co. VII, L.L.C.10 percent owner1,307,189$1.53$2.00M$4.32M
2025-09-11BUYYoung Richard Adirector15,151$1.65$25K$281K

Order Flow (FINRA, ~3w lag)

12.1%retail-10.4pp
34.7%dark+8.9pp
week of 2026-04-13
0%20%40%60%24-1125-0225-0525-0825-1126-0226-04retail (non-ATS)dark (ATS)
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.

Revenue Breakdown

Revenue Segments

By Product (2023-Q4)
Product$31.2M-42%
Application Subscriptions And Other Services$22.4M-12%
By Geography (2023-Q4)
UNITED STATES$29.2M-42%
EMEA$14.2MNEW
Asia Pacific$4.8M+73%
Latin America$3.9M-57%
All Other$1.5M-15%

Filing Risk Analysis

Filing Risk Scores

CAMP4 Therapeutics: Impending Dilution Avalanche and Derivative Accounting Volatility

Overall Risk
7/10
Fraud
3/10
Dilution
9/10
Insolvency
6/10
Earnings Overstated
4/10
Hidden Liabilities
7/10
Legal
2/10
Audit Warnings
5/10
Hidden Upside
4/10
Contextually Acceptable
6/10

Counter-Thesis

Counter-Thesis & Recent News

📰 Recent News

In March 2026, CAMP4 reported a significantly strengthened balance sheet with $109.5 million in cash, extending its operational runway into 2028. This liquidity was bolstered by a $17.5 million upfront payment from a new strategic collaboration with GSK to develop ASO drug candidates for neurodegenerative and kidney diseases. Additionally, the company completed an oversubscribed $50 million private placement and a $30 million underwritten equity offering. Progress on its lead candidate, CMP-002 (targeting SYNGAP1), includes ongoing GLP toxicology studies with a global Phase 1/2 trial expected to initiate in 2H 2026 (Source: Seeking Alpha, Nasdaq).

🐻 Bear Case

The primary bear thesis rests on the company's lack of near-term clinical catalysts, as the lead program will not enter human trials until late 2026, leaving a 'news vacuum.' Financial results for FY25 showed a widening net loss of $80.4 million, and the company recently paused internal investment in its CMP-001 program (Urea Cycle Disorders) to save costs, signaling a narrowing focus that increases R&D concentration risk (Source: TipRanks, BioSpace).

🚩 Red Flags

Shareholders have faced massive dilution, with total shares outstanding growing by approximately 157.7% in the past year. While cash levels are high, the FY25 net loss was exacerbated by a $29.8 million non-cash accounting loss related to derivative tranche liabilities. Furthermore, technical indicators remain weak, with the stock trading below key moving averages and maintaining negative MACD momentum (Source: Simply Wall St, TipRanks).

⚔️ Competitive Threats

CAMP4 faces competition from established players in the RNA-targeting and antisense oligonucleotide (ASO) space, such as Ionis Pharmaceuticals and Alnylam. In the specific SYNGAP1 and rare pediatric disease niche, other gene therapy and precision medicine firms are competing for limited patient populations and specialized clinical trial sites, which could delay their 2H 2026 trial targets (Source: Camp4 Corporate Update, Fintel).

💬 Customer Sentiment

Sentiment among the rare disease patient community remains a core strength; the company recently hosted a successful 'Family Day' event in Poland for the SYNGAP1 community, demonstrating high engagement with advocacy groups. Institutional sentiment shows potential for a 'smart money' turnaround, as major firms like Janus Henderson, Balyasny, and Adage Capital participated in the recent $100M+ funding rounds (Source: Traders Union, Simply Wall St).

Full Earnings Call Transcript

Full Earnings Call Transcript — Q3 • 2024-01-09

Operator: Good day and thank you for standing by. Welcome to the CalAmp Corp. FY ‘24 Q3 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Jikun Kim, Chief Financial Officer.
Jikun Kim: Good afternoon and welcome to CalAmp’s Q3 FY ‘24 financial results earnings call. My name is Jikun Kim. I am the Chief Financial Officer at CalAmp. Also with us today is CalAmp’s Interim President and Chief Executive Officer, Jason Cohenour. During today's call, we will make certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions, and as such are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from forward-looking statements in this communication. Investors should listen to today's call with the understanding that our actual results may be materially different from the plans, intentions, and expectations disclosed in the forward-looking statements that we are about to make. For more information about these risk factors that may cause actual results to differ materially from forward-looking statements, please refer to the earnings press release that we issued today as well as the company's filings within the Securities and Exchanges Commission. Investors are cautioned not to put undue reliance on these forward-looking statements. The company specifically disclaims any obligation to update the forward-looking statements that may be discussed during this call. Jason will begin today's call with the review of the company's recent operational highlights, and then I will provide a more detailed review of the financial results, followed by a question-and-answer session. With that, it is my great pleasure to turn the call over to CalAmp’s Interim President and Chief Executive Officer, Jason Cohenour. Jason, go ahead, please.
Jason Cohenour: Thank you, Jikun, and thanks to all of you for joining us on the call today. In the third quarter, CalAmp continued to see strength in certain areas of the business, while also experiencing demand softness in others. Specifically, our industrial and international connected car segments continued to perform well, whereas soft demand from TSP customers led to lower than expected consolidated revenue. Our view is that continued softness with TSPs is mainly related to the post-COVID supply chain correction and subsequent inventory rebalancing, as well as an intensified competitive environment in the overall telematics solution ecosystem. In response, we have reallocated strategic focus and resources to this segment and believe we are seeing early signs of recovery. We are optimistic that TSP revenue will stabilize and return to growth from current levels. Another complicating factor with our TSP customers has been a difficult but necessary migration from our legacy PULS device management system to its successor, DMCTC. I am very pleased to report that after 20 months of monumental effort and some pain, that the technical migration of more than 8.5 million devices to DMCTC is now essentially complete. All of our TSP customers can now look forward to fully leveraging the improved functionality and benefits of DMCTC as opposed to migrating devices. Furthermore, as the final strokes of the migration are completed, the CalAmp team can re-vector more of its time and attention to optimizing the customer experience and driving revenue growth. Overall, the company generated $53.6 million in revenue and $1 million of adjusted EBITDA in the quarter, both of which fell below our expectations at the time we provided directional commentary on October 5th. Adjusted EBITDA was lower than expected as a result of the lower revenue and gross margin. Non-GAAP OpEx was lower sequentially as a result of previous cost reduction initiatives, and this helped to cushion the impact of lower revenue and gross margin. On the product and sales front, the company continued to hone its focus on core market segments to maximize the effectiveness of our investments and resources. As a result, there were several developments in the quarter that we believe represent growth catalysts for the future. One of these developments was the release of an upgraded version of our AI dash cam solution, Vision 2.1. This new model offers the standalone video capabilities of Vision 2.0, but also includes other telematics functionality, such as GPS tracking, without the need for a separate gateway or LMU device. Vision 2.1 has now been released for our K-12 and commercial fleet applications. As previously mentioned, we had another extraordinarily strong quarter in the industrial segment, particularly with our large OEM customer. We are also seeing some very encouraging market traction with other industrial OEMs who are showing significant interest in the flexibility and computing power of CalAmp's edge software platform, EdgeCore. This edge platform, together with our DMCTC cloud, enables customized edge computing capabilities for proprietary edge apps, which can lead to lower operating costs, improved flexibility, and lower latency compared to traditional device-to-cloud solutions. We have customers integrating this unique edge capability today and are excited to expand our opportunity set with industrial OEMs. Also, our international connected car business continues to execute well, achieving several milestones in the quarter. First, we were granted Toyota Genuine certification, enabling our solutions to be installed at Toyota's ports, thereby streamlining the sales and customer delivery process and providing an opportunity for geographical expansion. Additionally, Jaguar Land Rover has endorsed our Stolen Vehicle Recovery system as its recommended solution to help mitigate the impact of a growing theft issue in the UK. Increasing theft of JLR's Range Rovers in the UK has led to significant increases in insurance premiums on these targeted models. With JLR's endorsement, select insurance companies are offering lower premiums on vehicles that have our SVR solution installed. We are encouraged by JLR's endorsement of our unique SVR technology and believe that it represents a catalyst for growth in the UK market and beyond. During the quarter, we also launched an initiative to narrow our strategic focus to market segments where we are particularly well positioned and see opportunities for profitable growth. In addition to concentrating our resources in those market segments with the best opportunity for growth, our narrower focus has also enabled us to take significant cost reduction actions. We estimate that our cost reduction actions will result in approximately $16 million in annualized savings compared to our fiscal Q2 run rate. We anticipate that approximately 75% of the savings will come from operating expenses and capital expenditures, with the balance coming from reductions in cost of goods. While we expect to see some immediate benefit from our cost reduction initiatives, the full impact will be realized throughout fiscal year ‘25. With these reductions, we expect to significantly strengthen the leverage in our operating model and to achieve adjusted EBITDA breakeven at approximately $42 million in quarterly revenue, depending on product mix and gross margins. On December 18, we announced the closing of a $45 million term loan with Lynrock Lake Master Fund LP. This new term loan replaces our previous asset-backed line of credit and enhances our strategic positioning as we engage with new and existing customers, partners, and suppliers. The new capital also provides financial flexibility in support of our strategy and business transformation. Lynrock is a longtime supporter of CalAmp and is an existing holder of a large majority of CalAmp’s 2% convertible senior notes, maturing in August of 2025. In connection with the execution of the term loan agreement, CalAmp is amending the notes to add a security interest. And finally, I'm very excited that we very recently announced the appointment of veteran technology leader Chris Adams as CalAmp's next President and CEO, effective January 22nd, 2024. Chris is an accomplished technology leader, will bring a wealth of knowledge and experience to CalAmp. He possesses a unique combination of technical depth, operational skills, and general management experience from a broad range of technology companies, most recently, as General Manager of the Automotive Sensing Division at onsemi. We have high confidence in Chris's ability to lead the company through its transformation and to greater value for customers and investors. As for me, I will continue to serve as CalAmp’s Interim CEO until Chris arrives. Following his arrival, I will work with him and the team to ensure a smooth handover of leadership responsibilities. Following the handover, I plan to resume my role as Independent Director for CalAmp. It has been a true pleasure to serve as CalAmp's Interim CEO and I can report without hesitation that the CalAmp team is talented and passionate and they believe in the opportunity before us. In addition to having a great team, the company also has other tremendous assets, including excellent products and solutions, a blue chip customer base, and a large and growing market opportunity. I look forward to supporting CalAmp's next chapter of profitable growth and market leadership. With that, I'll turn the call over to Jikun to discuss our third quarter financial results in more detail. Jikun?
Jikun Kim: Thank you, Jason, and thank you for stepping up during this transition. It has been a pleasure to work with you. My commentary will include reference to non-GAAP financial measures. A full reconciliation of these non-GAAP measures with the corresponding GAAP measure is included in the earnings release. Total revenues in the third quarter were $53.6 million. Revenues declined 32% year-over-year and 13% sequentially from $61.7 million last quarter. Much of the year-over-year and quarter-over-quarter revenue decline was driven by lower sales to our TSP customers, partially offset by strong performance in our industrial and connected car market segments. As Jason mentioned in his remarks, the revenue decline was driven by our TSP customers continuing to rebalance their inventories, while also navigating competitive pressures in their end markets. As we move into Q4, we are seeing early indications from our TSP customers that the business is stabilizing and orders have improved. Recurring application subscription revenue in the quarter were $17.8 million, a $900,000 sequential decline. While the total connected car market segment revenues were steady quarter over quarter, the decline in recurring revenue was driven by our connected car UK operations as a large insurance carrier exited the UK market in the quarter. These declines were partially offset by recurring revenue growth in our K-12 segment. Consolidated gross margin in the third quarter was 33%, compared to 36% in the prior quarter. The sequential gross margin decline was driven by unfavorable product mix, lower volumes, and higher-than-normal excess and obsolescence accruals and warranty expenses. E&O was largely driven by a set of SKUs from our cargo tracking product line and higher warranty expenses were the result of quality issues with one of our product SKUs, which has since been resolved. Third quarter GAAP operating expenses were $101 million. Excluding goodwill impairment, restructuring charges, expenses related to Jeff Gardner's passing, and other non-recurring expenses, third quarter operating expenses would have declined $2.5 million sequentially to approximately $23 million. The resulting Q3 FY ‘24 adjusted EBITDA was $1 million or 2% of revenues. Please see the press release for further details of our non-recurring adjustments. At the end of Q3 FY ‘24, we had total cash and cash equivalents of approximately $38.2 million as compared to $38.6 million last quarter. Cash flow from operations was a positive $1.8 million in the quarter. Free cash flow in the quarter was a negative $500,000. Towards the end of Q3 FY ‘24, we implemented a significant cost reduction initiative, targeting $16 million in annualized cash savings relative to Q2 FY ‘24 run rates. These savings should be fully realized by the end of FY ‘25. Approximately 25% of the reductions will come from cost of goods as new, lower cost and higher performance products replace aging products over time. The balance of the reductions will come from operating expenses and capital expenditures. With these reductions, our adjusted EBITDA breakeven should be reduced to approximately $42 million in quarterly revenues, depending on business mix and realized gross margins. In the quarter, we also assessed the carrying value of goodwill on our balance sheet. Driven by significant revenue declines in our TSP market segment, the fair value of some of the goodwill segment was determined to be less than the carrying value, and we recognized a $74 million goodwill impairment. Subsequent to the quarter end, we announced the closing of a strategic financing agreement with Lynrock Lake. The financing will provide additional liquidity and operating flexibility as we implement our restructuring efforts and return CalAmp to growth, profitability, and cash flow generation. As a note, term loan has no financial covenants. With this strategic financing and significantly lower cost structure, incremental revenues will create enhanced profitability and cash flows, positioning the company to execute on its plan to address the $230 million convertible loan coming due on August 1, 2025, and the $45 million term loan coming due December 15, 2027. From a business outlook standpoint, in Q4, we expect revenues from our industrial market segment to decrease from its recent multi-quarter highs to a more normalized level. We expect this revenue reduction in industrial to be partially offset by a recovery from our TSP customers. Overall, we expect the consolidated revenues to be down slightly and for the adjusted EBITDA to be stable relative to Q3 FY ‘24 levels. With that, I'll turn the call back to Jason for some final comments. Jason?
Jason Cohenour: Thank you, Jikun. In conclusion, I would like to thank everyone for their continued support of CalAmp. We have an unwavering belief in the value our technology services and employees bring to the market, and our team remains dedicated to capitalizing on that value and navigating the opportunities ahead. This concludes our prepared remarks. We will now open the call to your questions. Operator?
Operator: Thank you. [Operator Instructions] Our first question comes from Adam Beavis with Goldman Sachs. You may proceed.
Adam Beavis: Hi, this is Adam Beavis on for Jerry today. Thanks for taking my question. As a starting point, can you just put a finer point on what you're seeing in the TSP market that's driving your confidence that we could see a recovery here soon? And then, stepping back more broadly, how are you thinking about timing around return to revenue growth for the overall business? Thank you.
Jason Cohenour: Thanks, Adam. This is Jason. So I'll be abstract somewhat on the signals we're seeing from TSPs, but basically we're -- we are seeing order volume come up a bit. Our internal forecast is up. We're getting more favorable anecdotal commentary from our TSPs. So all of that leads us to believe that a recovery is underway. Being realistic, I think that recovery is going to be slow. We -- it's going to take us a while to get back up to historical levels, but like I said, we're optimistic. And our current view is, in Q4, we'll see a recovery relative to Q3. With respect to forward guidance beyond the commentary provided here on overall consolidated revenue, I think we're going to be cautious on that at this point in time, Adam, but I'd say on balance we're optimistic. The big negative moving piece for us has been in the past few quarters, TSPs, and we're seeing signs of recovery. As Jikun indicated in our prepared remarks, we're going to see kind of a return to normal for industrial. So that's going to work through the consolidated results. But overall, we're optimistic and we've got some -- we believe, growth catalysts in the business that'll play out over time.
Adam Beavis: Thanks for that. And then nice to see the closing of the $45 million term loan. Can you just update us on how you're thinking about other strategic options to address the 2025 convertible note?
Jikun Kim: Yeah. So I think we've discussed this in the past, Adam. So operationally, obviously, we're going to have to do better, right? Grow the business, increase profitability, and generate more cash. We believe these things will generate opportunities and flexibility options for us to be able to, one, potentially refinance a portion of all the debts coming due at a lower cost, as well as push out some of it, as well as pay off some of it at maturity. So fundamentally, the strategy really hasn't changed.
Adam Beavis: Okay, got it. And then just lastly for me, you folks have been focused on some new applications and solutions. Just wondering how the growth trajectory of some of those higher ARPU solutions have been and how you think about revenue subscriber trends over the next several quarters as you work to grow those newer applications and solutions.
Jason Cohenour: Sure, Adam. This is Jason. I'll talk to -- really Vision 2.1 has been kind of our most recent important launch in terms of an ARPU driver. That product has been now fully integrated with both our K-12 apps and our CalAmp app for commercial fleet. We're in market with it. We've got a handful of customer wins and installations, so we're kind of stepping into it now. We're optimistic there, and in particular around K-12. And the other dynamic around K-12 is they're back to business now after their normal seasonal quiet period as school opens, and of course through the holidays. So we're optimistic there. And other growth catalysts to point to outside the app are connected car. Connected car has, I think, a few good things happening. We've organically opened in Spain about 18 months ago. That business has now achieved breakeven and is continuing to grow. And based on the success there, we're evaluating other geographical expansion opportunities with connected car, mainly in Europe. And in addition to that, we've got some nice milestones -- customer milestones in that part of the business with both Toyota and Jaguar Land Rover that we believe can help us drive more growth in that area of the business.
Adam Beavis: Great. Thanks so much.
Operator: Thank you. [Operator Instructions] And I'm not showing any further questions. I would like to turn the call back over to Jason Cohenour for any closing remarks.
Jason Cohenour: Thank you, Josh. And thank you to everybody for joining us on the call today and for your continued interest in CalAmp. We look forward to speaking with you again during our fourth quarter and fiscal year 2024 earnings call. Josh, you can now disconnect the call.
Operator: Thank you. Thank you for your participation. You may now disconnect.